Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2010
11/01/2010CA2665302A1 Cd36 modulation and uses thereof
10/2010
10/28/2010WO2010123156A1 Angiogenesis inhibitor
10/28/2010WO2010123119A1 Therapeutic agent and screening method for inflammatory bowel disease
10/28/2010WO2010123102A1 Collagen production promoter, anti-photoaging agent, moisture-retention improvement agent, and composite for use on skin
10/28/2010WO2010123069A1 Method for diagnosing autoimmune disease patient, in vitro diagnostic agent and therapeutic agent therefor
10/28/2010WO2010123037A1 Agent for regulating composition ratio of intestinal bacterial flora
10/28/2010WO2010122453A1 A medicinal cream containing miconazole nitrate, hydrocortisone acetate, and a biopolymer, and a process to make it
10/28/2010WO2010121814A1 Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist
10/28/2010US20100273810 Method of treating cognitive impairments and schizophrenias
10/28/2010US20100273760 Topical Pharmaceutical Formulations And Methods Of Treatment
10/28/2010US20100273705 Method for inhibiting "Melanoma Inhibitory Activity" MIA
10/28/2010US20100273274 Polynucleotides encoding acetylcholine-gated chloride channel subunits of caenorhabditis elegans
10/28/2010US20100272823 Pulmonary delivery particles comprising water insoluble or crystalline active agents
10/28/2010US20100272822 Nanocell drug delivery system
10/28/2010US20100272729 Mammalian tumor susceptibility gene products and their uses
10/28/2010US20100272728 Mammalian tumor susceptibility gene products and their uses
10/28/2010US20100272726 Assays, methods and means
10/28/2010US20100272646 Method for inducing lymphoid tissue and modulating intestinal homeostasis
10/28/2010US20100272645 Myocardial perfusion imaging method
10/28/2010CA2759870A1 Particulate pharmaceutical composition with an opioid and an opioid antagonist
10/27/2010EP2243494A1 Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist.
10/27/2010EP2243493A1 Immunopotentiative composition
10/27/2010EP2243475A1 Combination of memantine and donepezil for treatment of CNS disorders
10/27/2010EP2242875A1 Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
10/27/2010EP1720557B1 Rapidly disintegrating taste-masked tablet
10/27/2010EP1330293B2 Controlled release composition comprising lactic acid polymer, and method of producing the same
10/27/2010EP1218509B9 Fibroblast growth factor-like polypeptides
10/27/2010EP1171124B2 Anthelmintic compositions
10/27/2010EP1112088B1 Method for detecting connective tissue growth factor for diagnosing a renal disorder
10/27/2010CN1678317B 1-amido-4-phenyl-4-benzyloxymethyl-piperidine derivatives and related compounds as neurokinin-1(NK-1) antagonists for the treatment of emesis, depression, anxiety and cough
10/27/2010CN1617742B Methods for treating cancer by using tumor-derived dentrical cell inhibitory factor antagonist in combination with toll-like receptor agonist
10/27/2010CN1585633B Phenethanolamine derivatives for treatment of respiratory diseases
10/27/2010CN101869711A Medicament composition containing diuretic antihypertensive medicament and biguanide antidiabetic medicament and applications thereof
10/27/2010CN101869710A Antihypertensive medical composite
10/27/2010CN101869709A Composite of peptic ulcer resisting medicaments and preparation method thereof
10/27/2010CN101869708A Medicament composition containing calcium channel blockers and biguanide antidiabetic medicine and application thereof
10/27/2010CN101279092B Applications of VEGF receptor fusion protein in preparation of medicament for curing diseases about angiogenesis
10/27/2010CN101028521B Oral colon positioning feed preparation based on electric spinning superfine nuclear fibre and its making method
10/26/2010USRE41884 Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
10/26/2010US7820876 Animal model for evaluating neurodegenerative disorders and identifying neuroprotective agents
10/26/2010US7820814 Inhibitors of kinases
10/26/2010US7820792 isoform of the alpha 2 delta -4 subunit of a voltage gated calcium channel; useful to identify modulators of the channel subunit; for cancer and inflammation
10/26/2010US7820722 Comprises a multi-carbon backbone having an at least partially neutralized carboxy or sulfonic functional group and also one or more side chains that have one or more carbon atoms and, optionally, one or more functional groups.
10/26/2010US7820718 inhibiting growth of a tumor comprising head and neck squamous carcinoma cells by contacting the tumor with an amount of paclitaxel, and an amount of C6-ceramide, sequentially or concomitantly
10/26/2010US7820715 Chemical intermediates; neurodegenerative disorders
10/26/2010US7820680 HIV integrase inhibitors
10/26/2010US7820671 Peptidomimetic protease inhibitors
10/26/2010US7820447 drug screening; for carcinomas, especially lymphoma carcinomas
10/26/2010US7820379 Process for high throughput screening of CpG-based immuno-agonist/antagonist
10/26/2010US7820199 for therapy of allergic and/or inflammatory conditions of the skin and airway passages; desloratadine-pseudoephedrine once-a-day product which produces a release rate profile for pseudoephedrine over an extended period in excess of twelve hours while maintaining delivery of desloratadine
10/26/2010US7820193 Anticancer agents; prevent forming blood vessels; removal blockage
10/26/2010US7820178 VEGF isoforms and their use as anti-angiogenic, anti-vasodilatory, anti-permeability and anti-proliferative agents
10/26/2010US7820175 Herbal therapy for the treatment of food allergy
10/26/2010US7820169 inhibiting the activity of tumor necrosis factor TNF in a patient having rheumatoid arthritis or psoriatic arthritis, by administering a composition comprising an effective amount of human anti-TNF antibody comprising a heavy chain variable region comprising SEQ ID NO:7 and a light chain variable
10/26/2010US7820161 Treatment of autoimmune diseases
10/26/2010US7820156 Inhibiting receptor of a cytokine-2 member of the interleukin-1 family as antiinflammatory agent; sepsis, liver,brain, or lung injuries; arthritis, psoriasis, inflammatory bowel disease
10/26/2010CA2564684C Use of thioxanthene derivatives as chemosensitising compounds
10/26/2010CA2516438C Treatment of inflammatory bowel disease
10/26/2010CA2487270C Antimicrobial compositions, products and methods employing same
10/26/2010CA2457780C Topical compositions and methods for treating pain
10/26/2010CA2434608C Promoting cell regeneration and/or cell differentiation with non-metabolizable sugar and a polymeric absorbent
10/26/2010CA2409698C Neural progenitor cell populations
10/26/2010CA2400700C Antiviral azaindole derivatives
10/26/2010CA2351887C Psca: prostate stem cell antigen and uses thereof
10/21/2010WO2010121175A1 Combination targeted therapy for lung cancer
10/21/2010WO2010120880A1 Treatment of liver diseases with a caspase inhibitor
10/21/2010WO2010120695A2 5-ht4 receptor agonist compounds for treatment of cognitive disorders
10/21/2010WO2010120253A1 Thiocolchicoside and non-steroidal anti-inflammatory drug combinations
10/21/2010WO2010119990A1 Pharmaceutical compositions
10/21/2010WO2010119698A1 Head-and-neck tumor proliferation inhibitor
10/21/2010WO2010119294A2 Composition
10/21/2010WO2010119132A1 Pharmaceutical composition comprising glycerol, white soft paraffin and liquid paraffin for the treatment of uremic xerosis and/or pruritus
10/21/2010WO2010118789A1 Hydroxytyrosol combinations for enhancing mitochondrial function and energy production
10/21/2010WO2010099139A3 Combination of an either an anti-igf-ir- antibody or an igf binding protein and a small molecule igf-ir kinease inhibitor
10/21/2010WO2010092163A3 Antidiabetic medications comprising a dpp-4 inhibitor (linagliptin) optionally in combination with other antidiabetics
10/21/2010WO2010091299A3 Combination of a 17 alpha-hydr0xylase/c17, 20-lyase inhibitor with an additional therapeutic agent
10/21/2010WO2010081647A3 Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
10/21/2010WO2010056985A3 Treatment of proteinopathies using a farnesyl transferase inhibitor
10/21/2010WO2010026602A3 Pharmaceutical compositions containing calcium channel blockers for treatment of tuberculosis
10/21/2010US20100268329 Drug/Drug Delivery Systems For The Prevention And Treatment Of Vascular Disease
10/21/2010US20100267930 SLO2 and SLO4, Novel Potassium Channel Proteins from Human Brain
10/21/2010US20100267924 Phosphorus-Containing Compounds with Polymeric Chains, and Methods of Making and Using the Same
10/21/2010US20100267798 Pharmaceutical formulations and use thereof in the prevention of stroke, diabetes and/or congestive heart failure
10/21/2010US20100267758 Pharmaceutical formulation
10/21/2010US20100267754 Integrin expression inhibitor
10/21/2010US20100267739 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance
10/21/2010US20100267736 Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
10/21/2010US20100267735 Methods and compositions to enhance the efficacy of phosphodiesterase inhibitors
10/21/2010US20100267685 Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones
10/21/2010US20100267621 Antimicrobial Compounds and Formulations
10/21/2010US20100267620 Methods for slowing senescence and treating and preventing diseases associated with senescence
10/21/2010US20100267046 Isoform-selective inhibitor and activators of pde3 cyclic nucleotide phosphodiesterases
10/21/2010US20100266705 Nanoparticulate megestrol formulations
10/21/2010US20100266698 Use of insulin for the treatment of cartilaginous disorders
10/21/2010US20100266674 L-oddc prodrugs for cancer
10/21/2010US20100266511 Pharmaceutical foam
10/21/2010DE69229688C5 Ophthalmische Zusammensetzungen, die Kombinationen von einem Carboanhydrase-Inhibitor und einem Beta-adrenergischen Antagonist enthalten Containing ophthalmic compositions comprising combinations of a carbonic anhydrase inhibitor and a beta-adrenergic antagonist
10/21/2010CA2758321A1 5-ht4 receptor agonist compounds for treatment of cognitive disorders
10/20/2010EP2241887A2 Diagnostics, drug screening and treatment for cancer
10/20/2010EP2241885A1 Agent and method for diagnosis on the occurrence of alzheimer's disease or the tendency to develop alzheimer's disease
1 ... 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 ... 1151